Mediclinic Southern Africa has acquired an 80% stake in Artisan Biomed to enhance its precision medicine services, marking a significant step towards personalized healthcare in South Africa.
Information on the Target
Mediclinic Southern Africa has made a significant move into precision medicine with the acquisition of an 80% stake in Artisan Biomed, a subsidiary of the Centre for Proteomic & Genomic Research (CPGR), which retains a 20% shareholding. This acquisition marks the inception of Mediclinic Precise, a series of DNA-based diagnostic and clinical interpretation services aimed at personalizing healthcare based on individual genetic profiles. The initiative is designed to enhance wellness, disease prevention, and health management strategies.
Artisan Biomed was established through CPGR’s accelerator program, which aims to foster the emergence of South African startups specializing in Omics technologies. This initiative is backed by the Department of Science and Innovation and supported financially by the Technology Innovation Agency. The firm possesses advanced genomics capabilities that deliver clinical insights in critical health areas such as oncology, reproductive health, pediatrics, pharmacogenetics, and nutrigenetics.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in South Africa
The healthcare landscape in South Africa is characterized by a dual system comprising both public and private sectors, with the private sector being comparatively advanced and well-funded. The emphasis on precision medicine is gaining traction due to increas
Similar Deals
Bambu Ventures → Lemonaid Health
2026
Mediclinic Southern Africa
invested in
Artisan Biomed
in 2023
in a Buyout deal